Newswise — A practical resource-based public health approach for the rapid initiation of antiretroviral therapy in HIV-infected individuals living in low- and middle-income countries could save thousands of lives, according to an Essay published January 15 in the open-access journal PLOS Medicine by Mark Tenforde of the University of Washington School of Medicine, and colleagues.

Effective antiretroviral therapy has substantially decreased HIV morbidity and mortality over the past two decades. Several randomized trials have demonstrated benefits from starting antiretroviral therapy regardless of CD4 count, and the World Health Organization adopted a “treat all” strategy in 2015. Significant attention has been focused on rapidly initiating antiretroviral therapy in different settings, and considerable progress has been made. Yet a significant proportion of patients starting antiretroviral therapy in low- and middle-income countries continue to present with severe immunosuppression, with recent laboratory-based surveillance showing that one-third of South African patients enter care with advanced HIV disease. These late presenters have the highest risk for immune reconstitution inflammatory syndrome, unmasking of opportunistic infections including tuberculosis, and death.

According to Tenforde and colleagues, current strategies are inadequate for identifying and preventing opportunistic infections and related deaths in late presenters. The authors present a resource-based approach according to diagnostic test availability for targeting opportunistic infections in the “treat all” era. The approach could decrease early mortality after antiretroviral therapy initiation and would be practical to implement. Even the most resource-constrained settings can implement interventions that have the potential to save thousands of lives, while further refinement can be offered in settings where rapid screening for common opportunistic infections is feasible.

According to the authors, an optimal approach requires that pre-antiretroviral therapy CD4 testing continues to be available (preferably as a simple point-of-care threshold test), although viral load testing has been supplanting CD4 testing in high-burden countries in the “treat all” era. “We believe this provides a pragmatic algorithm to avoid delaying antiretroviral therapy for the most immunosuppressed patients who are at the highest risk of dying,” the authors write.

Research Article


The authors received no specific funding for this work.



Tenforde MW, Walker AS, Gibb DM, Manabe YC (2019) Rapid antiretroviral therapy initiation in low- and middle-income countries: A resource-based approach. PLoS Med 16(1): e1002723.

Author Affiliations:

Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington School of Medicine, Seattle, Washington, United States of America

Department of Epidemiology, University of Washington School of Public Health, Seattle, Washington, United States of America

Botswana-UPenn Partnership, Gaborone, Botswana

Medical Research Council Clinical Trials Unit at University College London, London, United Kingdom

Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America

Infectious Diseases Institute, Makerere University College of Health Sciences, Kampala, Uganda

Press-Only Preview of the Article:

In your coverage please use this URL to provide access to the freely available paper:


Mark Tenforde

University of Washington

1959 NE Pacific Street

Seattle, 98195


[email protected]

About PLOS Medicine

PLOS Medicine publishes articles on biomedical, environmental, social and political determinants of human health worldwide. The journal accepts a variety of study designs including clinical trials, observational studies, diagnostic and prognostic tools, epidemiology, predictive and explanatory modeling, qualitative studies and clinically oriented translational research.  For more information, visit, and follow @PLOSMedicine on Twitter.

Media and Copyright Information

For information about PLOS Medicine relevant to journalists, bloggers and press officers, including details of our press release process and embargo policy, visit

PLOS journals publish under a Creative Commons Attribution License, which permits free reuse of all materials published with the article, so long as the work is cited. 

About the Public Library of Science
Public Library of Science (PLOS) is a nonprofit Open Access (OA) publisher, innovator and advocacy organization dedicated to accelerating progress in science and medicine by leading a transformation in research communication. The PLOS suite of journals contain rigorously peer-reviewed Open Access research articles from all areas of science and medicine, together with expert commentary and analysis. In addition to journals, the organization advances innovations in scientific publishing through Collections, Communities and The PLOS Blog Network. Founded to catalyze a revolution in scientific publishing by demonstrating the value and feasibility of Open Access publication, PLOS is committed to innovative and forward-looking solutions to scientific communication. For more information, visit